ZA201000423B - Self complementary aav-mediated delivery of interfering rna molecules to treator prevent ocular disorders - Google Patents

Self complementary aav-mediated delivery of interfering rna molecules to treator prevent ocular disorders

Info

Publication number
ZA201000423B
ZA201000423B ZA2010/00423A ZA201000423A ZA201000423B ZA 201000423 B ZA201000423 B ZA 201000423B ZA 2010/00423 A ZA2010/00423 A ZA 2010/00423A ZA 201000423 A ZA201000423 A ZA 201000423A ZA 201000423 B ZA201000423 B ZA 201000423B
Authority
ZA
South Africa
Prior art keywords
rna molecules
interfering rna
mediated delivery
ocular disorders
self complementary
Prior art date
Application number
ZA2010/00423A
Other languages
English (en)
Inventor
Allan R Shepard
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of ZA201000423B publication Critical patent/ZA201000423B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA2010/00423A 2007-10-01 2010-01-20 Self complementary aav-mediated delivery of interfering rna molecules to treator prevent ocular disorders ZA201000423B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97655207P 2007-10-01 2007-10-01
PCT/US2008/078380 WO2009046059A1 (en) 2007-10-01 2008-10-01 Self complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders

Publications (1)

Publication Number Publication Date
ZA201000423B true ZA201000423B (en) 2011-03-30

Family

ID=40042637

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/00423A ZA201000423B (en) 2007-10-01 2010-01-20 Self complementary aav-mediated delivery of interfering rna molecules to treator prevent ocular disorders

Country Status (12)

Country Link
US (1) US20090087413A1 (https=)
EP (1) EP2192926A1 (https=)
JP (1) JP2010540564A (https=)
KR (1) KR20100061792A (https=)
CN (1) CN101815536A (https=)
AU (1) AU2008308784B2 (https=)
BR (1) BRPI0817937A2 (https=)
CA (1) CA2694091A1 (https=)
MX (1) MX2010001608A (https=)
RU (1) RU2010117178A (https=)
WO (1) WO2009046059A1 (https=)
ZA (1) ZA201000423B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
EP2287323A1 (en) * 2009-07-31 2011-02-23 Association Institut de Myologie Widespread gene delivery to the retina using systemic administration of AAV vectors
SG10201800541SA (en) 2010-04-23 2018-03-28 Univ Florida Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)
CN103505743A (zh) 2012-06-21 2014-01-15 北京命码生科科技有限公司 含功能性microRNA/siRNA的细胞微粒子及其应用
SG11201702055PA (en) * 2014-09-16 2017-04-27 Genzyme Corp Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
PL4012035T3 (pl) * 2014-09-16 2025-03-24 Genzyme Corporation Wektory wirusowe związane z adenowirusami do leczenia jaskry miocylinowej (myoc)
EP4012035B1 (en) * 2014-09-16 2024-11-06 Genzyme Corporation Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
GB201809588D0 (en) * 2018-06-12 2018-07-25 Univ Bristol Materials and methods for modulating intraocular and intracranial pressure
KR20220076510A (ko) 2019-10-08 2022-06-08 트러스티스 오브 보스톤 칼리지 다수의 서로 다른 비천연 아미노산을 함유하는 단백질 및 이러한 단백질의 제조 및 사용 방법
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物
WO2021245224A1 (en) * 2020-06-05 2021-12-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating ocular diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318923T1 (de) * 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
US20040198682A1 (en) * 2001-11-30 2004-10-07 Mcswiggen James RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US20050048529A1 (en) * 2002-02-20 2005-03-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20040209832A1 (en) * 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2005019422A2 (en) * 2003-08-13 2005-03-03 The Board Of Trustees Of The University Of Illinois Silencing of tgf-beta receptor type ii expression by sirna
WO2006042252A2 (en) * 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Viral complement control proteins for eye disorders
TWI401316B (zh) * 2004-12-23 2013-07-11 Alcon Inc 用於治療青光眼之血清澱粉樣蛋白Ａ的ＲＮＡｉ抑制作用
TWI386225B (zh) * 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
TW200639252A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular hypertension targets
WO2006099353A1 (en) * 2005-03-11 2006-09-21 Alcon, Inc. Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
GB0521351D0 (en) * 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
AR057252A1 (es) * 2005-12-27 2007-11-21 Alcon Mfg Ltd Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
TW200731980A (en) * 2005-12-29 2007-09-01 Alcon Mfg Ltd RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis
TW201336514A (zh) * 2006-04-13 2013-09-16 Alcon Res Ltd ＲＮＡ干擾（ＲＮＡｉ）所媒介之與脾酪胺酸激酶相關之發炎症狀的抑制作用（二）
WO2007127428A2 (en) * 2006-04-28 2007-11-08 University Of Florida Research Foundation, Inc. Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery
US7732421B2 (en) * 2006-05-19 2010-06-08 Alcon Research, Ltd. RNAI-mediated inhibition of tumor necrosis factor α-related conditions
KR20090042297A (ko) * 2006-08-24 2009-04-29 알콘 리서치, 리미티드 ＩＯＰ―관련 증상을 치료하기 위한 그렘린의 ＲＮＡｉ 매개 억제
US7872119B2 (en) * 2007-02-26 2011-01-18 Quark Pharmaceuticals, Inc. Inhibitors of RTP801 and their use in disease treatment
US7973019B1 (en) * 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
TW200932274A (en) * 2007-12-18 2009-08-01 Alcon Res Ltd Interfering RNA delivery system and uses thereof

Also Published As

Publication number Publication date
KR20100061792A (ko) 2010-06-09
CN101815536A (zh) 2010-08-25
CA2694091A1 (en) 2009-04-09
US20090087413A1 (en) 2009-04-02
AU2008308784A1 (en) 2009-04-09
BRPI0817937A2 (pt) 2015-04-07
RU2010117178A (ru) 2011-11-10
EP2192926A1 (en) 2010-06-09
AU2008308784B2 (en) 2013-07-18
JP2010540564A (ja) 2010-12-24
WO2009046059A1 (en) 2009-04-09
MX2010001608A (es) 2010-03-15

Similar Documents

Publication Publication Date Title
ZA201000423B (en) Self complementary aav-mediated delivery of interfering rna molecules to treator prevent ocular disorders
ZA201000246B (en) Improvements relating to the fitting of spectacles
EP2242504A4 (en) Therapeutic compositions for treatment of ocular inflammatory disorders
IL201183A0 (en) Administering antisense oligonucleotides complementary to human apolipoprotein b
SI2044111T1 (sl) Ciljanje komplementa faktorja H za zdravljenje bolezni
EP2152316A4 (en) THERAPEUTIC DELIVERY OF INHIBITORY NUCLEIC ACID MOLECULES IN THE RESPIRATORY SYSTEM
GB0719161D0 (en) Improvements relating to fabrick treatment compositions
IL202083A0 (en) Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
PL2049132T3 (pl) Nowe środki do leczenia zaburzeń związanych z osłabionym neuroprzekaźnictwem
BR112012011195A2 (pt) Oligonucleotídeo antissentido, composição e respectivo uso.
EP2207802A4 (en) INTRANASAL ADMINISTRATION OF ACTIVE AGENTS ON THE CENTRAL NERVOUS SYSTEM
ZA201106294B (en) Treatment of dyskinesia related disorders
IL206044A0 (en) Isoxazole derivatives as modulators of 11-beta-hydroxysteroid dehydrogenase type 1
IL194189A0 (en) Combination treatment of metabolic disorders
IL209868A0 (en) Improved peptide mediators of cholesterol effluk
EP2313099A4 (en) USE OF RIFALAZIL TO TREAT COLON DISEASES
PL2022504T3 (pl) Maść do leczenia hemoroidów
GB2448309B (en) Improvements relating to effluent discharge
PL1864668T3 (pl) Wykorzystanie proleku do okulistycznego podawania śródszklistkowego
EP2252881A4 (en) COMPLETE STRUCTURAL BREAKDOWN OF MOLECULES WITH SINGLE NMR EXPERIMENT
GB0809476D0 (en) Treatment of neurodegenerative disorders
ZA201006228B (en) Combined use of cholestanol derivative
PL2323625T3 (pl) Nowa kompozycja do leczenia pigmentacji wybroczynowych
HK1144391A (en) Self complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders
AP2010005307A0 (en) New therapeutic uses of dual molecules containing a peroxide derivative